黄芪注射液加低分子肝素治疗肾病综合征高凝状态临床研究

Effect of astragalus with heparin in treating high coagulable blood in children with nephrotic syndrome

目的探讨黄芪注射液加低分子肝素钙治疗原发性肾病综合征(Nephrotic syndrome,NS)高凝状态的疗效及安全性。方法54例原发性肾病综合征伴高凝状态患者,随机分为治疗组27例,对照组27例,所有患儿均常规泼尼松、血管紧张素转换酶抑制剂治疗,治疗组同时给予黄芪注射液和低分子肝素钙治疗,观察尿蛋白定量、血清白蛋白、胆固醇、凝血指标的变化。结果治疗4周,治疗组尿蛋白定量及血D-二聚体均低于对照组,治疗8周,血清白蛋白恢复与对照组比较差异有统计学意义。结论黄芪注射液加低分子肝素钙配合激素治疗肾病综合征高凝状态效果显著,对缩短疗程,减少复发,防治血栓形成有重要意义。

Objective To evaluate the effect and safety of astragalus with low molecular weight heparin in treating nephrotic syndrome （NS） with hypercoagulable state. Mothods 54 patients with nephrotic syndrome with hypercoagulable state were randomly divided into treatment group and control group of 27 patients. All patients were given ordinary treatment with prednisone and angiotensin converting enzyme inhibitor. The treatment group was treated with astragalus injection and low molecular weight heparin simultaneously. Urine protein excretion, serum albumin and cholesterol clotting index were observed. Results After 4 weeks＇ treatment, the urine protein excretion and D-dimer of the treatment group are lower than those of the control group （P〈0.05）. After 8 weeks＇ treatment, the recoveries of indexes of urine protein excretion, serum albumin and serum cholesterol of the treatment group were significant difference （P〈0.01） compared to those of the control group. Conclusions The astragalus injection with low molecular weight heparin combined with glucocorticoid demonstrats significant curative effect and great value in shortening the course of treatment and reducing the relapse and preventing from thrombosis in the treatment of NS with hypercoagulable state.